Package Leaflet: Information for the User
Effentora 100micrograms buccal tablets
Effentora 200micrograms buccal tablets
Effentora 400micrograms buccal tablets
Effentora 600micrograms buccal tablets
Effentora 800micrograms buccal tablets
Fentanyl
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
The active substance of Effentora is fentanyl citrate. Effentora is a medicine for the treatment of pain, this medicine is known as an opioid used to treat breakthrough pain in adult patients who are already receiving opioid treatment for their persistent (ongoing) cancer pain.
Breakthrough pain is a pain that comes on quickly and is in addition to your ongoing pain, despite your regular pain medicine.
Do not use Effentora:
Warnings and precautions
While you are being treated with Effentora, continue to use the opioid pain medicine that you take for your persistent cancer pain.
While you are being treated with Effentora, do not use any other fentanyl treatments that you may have been prescribed for breakthrough pain. If you still have these fentanyl products at home, speak to your pharmacist who will advise you how to dispose of them.
Repeated use of Effentora may lead to tolerance (where you need a higher dose to achieve the same level of pain relief) or physical dependence (you experience withdrawal symptoms if you stop using the medicine).
Tell your doctor or pharmacist BEFOREyou start using Effentora:
You may need to be closely monitored by your doctor:
Tell your doctor DURINGtreatment with Effentora:
Seek IMMEDIATEmedical help:
What to do if someone accidentally takes Effentora
If you think someone has accidentally taken Effentora, seek immediate medical help. Try to keep the person awake until the emergency services arrive.
If someone accidentally takes Effentora, they may experience the same side effects as described in the section “If you use more Effentora than you should”.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age.
Using Effentora with other medicines
Tell your doctor or pharmacist before starting treatment with Effentora if you are taking, have recently taken or might take any other medicines, including:
However, if your doctor prescribes Effentora with sedative medicines, the dose and duration of concomitant treatment should be limited by your doctor.
Tell your doctor about all sedative medicines you are taking (such as sleeping pills, medicines to treat anxiety, some medicines to treat allergic reactions [antihistamines] or tranquilizers) and follow your doctor’s dose recommendation carefully. It may be useful to inform friends or family members to be aware of the signs and symptoms described above. Contact your doctor if you experience these symptoms.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Using Effentora with food, drinks and alcohol
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Pregnancy
Effentora should not be used during pregnancy, unless you have discussed this with your doctor.
If Effentora is used for a long time during pregnancy, there is a risk that the newborn baby will experience withdrawal symptoms which can be life-threatening if not identified and treated by a doctor.
Do not use Effentora during labour, as fentanyl can cause breathing difficulties in the newborn baby.
Breast-feeding
Fentanyl may pass into breast milk and cause side effects in the breast-fed baby. Do not use Effentora if you are breast-feeding. You should not start breast-feeding until at least 5 days after the last dose of Effentora.
Driving and using machines
Ask your doctor if you can drive or use machines safely after taking Effentora. Do not drive or use machines if: you feel drowsy or dizzy, you have blurred vision or double vision or you have difficulty concentrating. It is important that you know how Effentora affects you before driving or using machines.
Effentora contains sodium
Effentora100micrograms
This medicine contains 10 mg of sodium (a major component of cooking/table salt) in each buccal tablet. This is equivalent to 0.5% of the maximum recommended daily intake of sodium for an adult.
Effentora200micrograms, Effentora400micrograms, Effentora600micrograms, Effentora800micrograms
This medicine contains 20 mg of sodium (a major component of cooking/table salt) in each buccal tablet. This is equivalent to 1% of the maximum recommended daily intake of sodium for an adult.
Follow your doctor's administration instructions for this medication exactly. If you are unsure, consult your doctor or pharmacist again.
Dosage and frequency
When you start using Effentora for the first time, your doctor will help you find the dose that will relieve your breakthrough pain. It is very important that you use Effentora exactly as your doctor tells you. The initial dose is 100 micrograms.
During the determination of the correct dose for you, your doctor may have you take more than one tablet per episode. If the breakthrough pain is not relieved after 30 minutes, use only 1 more Effentora tablet during the dose adjustment period.
Once you have determined the correct dose with your doctor, use 1 tablet for a breakthrough pain episode as a general rule. The dose of pain reliever you need may vary over time. You may need higher doses. If the breakthrough pain is not relieved after 30 minutes, use only 1 more Effentora tablet during this dose adjustment period.
Consult your doctor if your correct dose of Effentora does not relieve your breakthrough pain. Your doctor will decide if it is necessary to change your dose.
Wait at least 4 hours before treating another episode of breakthrough pain with Effentora.
You should inform your doctor immediately if you need to take Effentora more than four times a day, as it may be necessary to change your treatment regimen. Your doctor may change the treatment you are receiving to control persistent pain; when the persistent pain is controlled, your doctor may need to change your dose of Effentora. If your doctor suspects increased sensitivity to pain (hyperalgesia) related to Effentora, a reduction in the dose of Effentora may be considered (see section 2, "Warnings and precautions"). For more effective relief, inform your doctor of the pain you are experiencing and how Effentora is working for you, so that they can modify the dose if necessary.
Do not change the doses of Effentora or other pain relievers on your own. Any change in dosage must be prescribed and monitored by your doctor.
If you are unsure of the correct dose or want to ask a question about using this medication, contact your doctor.
Method of administration
The method of administration of Effentora oral tablets is by the oral route. When you place a tablet in your mouth, it dissolves and the medication is absorbed through the oral mucosa and into the bloodstream. This way of taking the medication allows it to be absorbed quickly to relieve your breakthrough pain.
How to use the medication
If you use more Effentora than you should
If you forget to use Effentora
If the breakthrough pain persists, you can take Effentora as directed by your doctor. If the breakthrough pain has disappeared, do not take Effentora until the next episode of breakthrough pain.
If you stop treatment with Effentora
You should stop Effentora when you no longer have any breakthrough pain. However, you should continue to take your usual opioid pain medication to treat persistent cancer pain, as directed by your doctor. When you stop treatment with Effentora, you may experience withdrawal symptoms similar to the possible adverse effects of Effentora. If you experience withdrawal symptoms or are concerned about pain relief, you should consult your doctor. Your doctor will assess whether you need medication to reduce or eliminate withdrawal symptoms.
If you have any further questions about using this medication, ask your doctor or pharmacist.
Like all medications, this medication can cause side effects, although not everyone will experience them. If you notice any of them, inform your doctor.
Serious side effects
Together, these symptoms can be a sign of a potentially life-threatening condition called adrenal insufficiency, in which the adrenal glands do not produce enough hormones.
Other side effects
Very common:may affect more than 1 in 10 patients
Common:may affect up to 1 in 10 patients
Uncommon:may affect up to 1 in 100 patients
Rare:may affect up to 1 in 1,000 patients
Unknown:frequency cannot be estimated from available data
Reporting side effects
If you experience any side effects, consult your doctor or pharmacist, even if they are possible side effects not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.
Effentora is a very strong pain reliever and can be life-threatening if taken accidentally by a child. This medication should be kept out of sight and reach of children.
Composition of Effentora
The active ingredient is fentanyl. Each tablet contains:
The other ingredients are mannitol, sodium carboxymethyl starch type A, sodium hydrogen carbonate, sodium carbonate, citric acid, magnesium stearate.
Appearance of the product and package contents
The oral tablets are flat, round, with beveled edges, and engraved on one side with a "C" and on the other with "1" for Effentora 100 micrograms, with "2" for Effentora 200 micrograms, with "4" for Effentora 400 micrograms, with "6" for Effentora 600 micrograms, and with "8" for Effentora 800 micrograms.
Each blister pack contains 4 oral tablets, which are available in cartons of 4 or 28 oral tablets.
Not all pack sizes may be marketed.
Marketing authorization holder
TEVA B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
Manufacturer
Teva Pharmaceuticals Europe B.V.
Swensweg 5
2031 GA Haarlem
Netherlands
You can obtain more information about this medication by contacting the local representative of the marketing authorization holder or by calling the following number:
Belgium Teva Pharma Belgium N.V./S.A./AG Tel: +32 3 820 73 73 | Lithuania UAB Teva Baltics Tel: +370 5 266 02 03 |
Bulgaria ???? ????? ??? Tel: +359 2 489 95 85 | Luxembourg Teva Pharma Belgium N.V./S.A./AG Tel: +32 3 820 73 73 |
Czech Republic Teva Pharmaceuticals CR, s.r.o. Tel: +420 251 007 111 | Hungary Teva Gyógyszergyár Zrt. Tel: +36 1 288 64 00 |
Denmark Teva Denmark A/S Tel: +45 44 98 55 11 | Malta Teva Pharmaceuticals Ireland Ireland Tel: +44 (0) 207 540 7117 |
Germany TEVA GmbH Tel: +49 731 402 08 | Netherlands Teva Nederland B.V. Tel: +31 (0) 800 0228 400 |
Estonia UAB Teva Baltics Eesti filiaal Tel: +372 661 0801 | Norway Teva Norway AS Tel: +47 66 77 55 90 |
Greece Specifar Α.Β.Ε.Ε. Tel: +30 211 880 5000 | Austria ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97007 0 |
Spain Teva Pharma, S.L.U. Tel: +34 91 387 32 80 | Poland Teva Pharmaceuticals Polska Sp. z o.o. Tel: +48 22 345 93 00 |
France Teva Santé Tel: +33 1 55 91 78 00 | Portugal Teva Pharma - Produtos Farmacêuticos, Lda. Tel: +351 21 476 75 50 |
Croatia Pliva Hrvatska d.o.o. Tel: +385 1 37 20 000 | Romania Teva Pharmaceuticals S.R.L. Tel: +4021 230 65 24 |
Ireland Teva Pharmaceuticals Ireland Tel: +44 (0) 207 540 7117 | Slovenia Pliva Ljubljana d.o.o. Tel: +386 1 58 90 390 |
Iceland Teva Pharma Iceland ehf. Tel: +354 550 3300 | Slovakia TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 257 267 911 |
Italy Teva Italia S.r.l. Tel: +39 028917981 | Finland Teva Finland Oy Tel: +358 20 180 5900 |
Cyprus Specifar Α.Β.Ε.Ε. Tel: +30 211 880 5000 | Sweden Teva Sweden AB Tel: +46 (0) 42 12 11 00 |
Latvia UAB Teva Baltics filiale Latvija Tel: +371 67 323 666 | United Kingdom(Northern Ireland) Teva Pharmaceuticals Ireland Ireland Tel: +44 (0) 207 540 7117 |
Date of last revision of this leaflet:July 2021
Detailed information about this medication is available on the European Medicines Agency website: http://www.ema.europa.eu/